Pregabalina w dawkach 300 mg/dobę i wyższych – bilans korzyści i ryzyka

• Authors: Anna Z. Antosik-Wójcińska , Łukasz Święcicki

Title variants

EN

Pregabalin at doses of 300 mg/day and higher – benefit and risk balance

• Languages of publication: PL

Abstracts

PL

W artykule przedstawiono obszerny przegląd badań dotyczących stosowania pregabaliny, głównie w terapii zaburzeń lękowych, ze szczególnym uwzględnieniem zespołu lęku uogólnionego. Zostały również krótko wspomniane inne możliwe zastosowania tego leku. Pregabalina jest ligandem podjednostki alfa-2-delta napięciowozależnych kanałów wapniowych zlokalizowanych na zakończeniach neuronów w mózgu i rdzeniu kręgowym. Przeprowadzono szereg badań wskazujących na to, że pregabalina to lek istotnie skuteczniejszy od placebo w terapii zespołu lęku uogólnionego, także przebiegającego z wyraźnie nasilonymi objawami depresji. Oceniano różne dawki pregabaliny – od 150 do 600 mg/dobę. Niższe dawki (od 150 mg/dobę) są skuteczne w zwalczaniu psychicznych objawów lęku, jednak leczenie objawów somatycznych wymaga przeważnie stosowania dawek wyższych (300 i więcej mg/dobę). Pregabalina jest lekiem z reguły dobrze tolerowanym. Do najczęściej wymienianych objawów niepożądanych zalicza się zawroty głowy, senność i uczucie oszołomienia. Donoszono też o występowaniu objawów odstawiennych przy zbyt gwałtownym zmniejszaniu dawki leku. Niektórzy autorzy zwracają uwagę na potencjał uzależniający pregabaliny, jednak wydaje się, że ryzyko nadużywania leku istnieje przede wszystkim w szczególnej podgrupie osób, które w przeszłości nadużywały substancji psychoaktywnych.

EN

The paper gives a broad review of studies on the use of pregabalin, mainly its potential in the therapy of anxiety disorders, with particular emphasis on generalized anxiety, while also briefly discussing its other possible applications. Pregabalin is a ligand for voltage-gated alpha-2-delta calcium channel subunits localised at presynaptic terminal regions in brain and spinal cord neurons. Multiple studies have demonstrated its higher efficiency over placebo in treating generalized anxiety disorder, including anxiety with aggravated depression symptoms. Different pregabalin doses, ranging from 150 to 600 mg/day, have been assessed, showing lower doses (starting from 150 mg/day) to be effective in treating the psychological symptoms of anxiety. Effective treatment of somatic symptoms, on the other hand, requires more aggressive dosing (doses of 300 mg/day and more). Pregabalin tends to be well tolerated, with the most commonly cited adverse effects including dizziness, drowsiness and confusion. There have also been reports of withdrawal symptoms following abrupt or rapid dose reduction. According to some authors, pregabalin can cause physical dependency, yet the risk for potential abuse seems to be present mainly in the group of patients with a history of psychoactive substance abuse.

Keywords

EN

bezpieczeństwo; pregabalina; wysokie dawki

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Psychiatria i Psychologia Kliniczna
• Year: 2017
• Volume: 17
• Issue: 3
• Pages: 208–215

Contributors

author

Anna Z. Antosik-Wójcińska

• II Klinika Psychiatryczna, Oddział Chorób Afektywnych, Instytut Psychiatrii i Neurologii, Warszawa, Polska

author

Łukasz Święcicki

• II Klinika Psychiatryczna, Oddział Chorób Afektywnych, Instytut Psychiatrii i Neurologii, Warszawa, Polska

References

• Anderson C, George D, Quante A: Pregabalin in acute treatment of anxious depression: a case series. Psychiatry Res 2014; 215: 246–248.
• Arezzo JC, Rosenstock J, LaMoreaux L et al.: Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008; 8: 33.
• Arroyo S, Anhut H, Kugler AR et al.; Pregabalin 1008-011 International Study Group: Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45: 20–27.
• Bech P: Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007; 40: 163–168.
• Ben-Menachem E: Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl 6: 13–18.
• Brodie MJ, Wilson EA, Wesche DL et al.: Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46: 1407–1413.
• Byers AL, Yaffe K, Covinsky KE et al.: High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. Arch Gen Psychiatry 2010; 67: 489–496.
• Crofford LJ, Rowbotham MC, Mease PJ et al.; Pregabalin 1008-105 Study Group: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264–1273.
• Cvjetkovic-Bosnjak M, Soldatovic-Stajic B, Babovic SS et al.: Pregabalin versus sertraline in generalized anxiety disorder. An open label study. Eur Rev Med Pharmacol Sci 2015; 19: 2120–2124.
• Diaper A, Rich AS, Wilson SJ et al.: Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum Psychopharmacol 2013; 28: 562–575.
• Feltner DE, Crockatt JG, Dubovsky SJ et al.: A randomized, doubleblind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–249.
• Feltner DE, Liu-Dumaw M, Schweizer E et al.: Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011; 26: 213–220.
• Feltner D, Wittchen HU, Kavoussi R et al.: Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23: 18–28.
• French JA, Kugler AR, Robbins JL et al.: Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631–1637.
• Gahr M, Freudenmann RW, Hiemke C et al.: Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 2013; 69: 1335–1342.
• Karaiskos D, Pappa D, Tzavellas E et al.: Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder – an open-label study. Int J Geriatr Psychiatry 2013; 28: 100–105.
• Kasper S, Herman B, Nivoli G et al.: Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a doubleblind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24: 87–96.
• Kasper S, Iglesias-García C, Schweizer E et al.: Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol 2014; 17: 685–695.
• Kavoussi R: Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006; 16 Suppl 2: S128–S133.
• Lydiard RB, Rickels K, Herman B et al.: Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13: 229–241.
• Montgomery SA, Lyndon G, Almas M et al.: Early Improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis. Int Clin Psychopharmacol 2017; 32: 41–48.
• Montgomery SA, Tobias K, Zornberg GL et al.: Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771–782.
• Montgomery S, Chatamra K, Pauer L et al.: Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008; 193: 389–394.
• Olivares JM, Álvarez E, Carrasco JL et al.: Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. Int Clin Psychopharmacol 2015; 30: 265–271.
• Oulis P, Kalogerakou S, Anyfandi E et al.: Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Hum Psychopharmacol 2014; 29: 224–229.
• Oulis P, Mourikis I, Konstantakopoulos G.: Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2011; 26: 221–224.
• Pande AC, Crockatt JG, Feltner DE et al.: Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160: 533–540.
• Pande AC, Feltner DE, Jefferson JW et al.: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24: 141–149.
• Pérez C, Latymer M, Almas M et al.: Does duration of neuropathic pain impact the effectiveness of pregabalin? Pain Pract 2017; 17: 470–479.
• Pohl RB, Feltner DE, Fieve RR et al.: Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebocontrolled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151–158.
• Ramzy EA: Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study. Pain Pract 2017; 17: 32–40.
• Randinitis EJ, Posvar EL, Alvey CW et al.: Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003; 43: 277–283.
• Reinhold JA, Rickels K: Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother 2015; 16: 1669–1681.
• Rickels K, Pollack MH, Feltner DE et al.: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, doubleblind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–1030.
• Rickels K, Rynn M, Iyengar M et al.: Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67: 41–47.
• Rickels K, Shiovitz TM, Ramey TS et al.: Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012; 27: 142–150.
• Schaffer LC, Schaffer CB, Miller AR et al.: An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. J Affect Disord 2013; 147: 407–410.
• Schifano F: Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014; 28: 491–496.
• Stein DJ, Baldwin DS, Baldinetti F et al.: Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18: 422–430.
• Święcicki Ł: Pregabalina w terapii zaburzeń lękowych. Psychiatr Psychol Klin 2015; 15: 141–147.
• Toth C: Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014; 5: 38–56.
• Tzellos TG, Toulis KA, Goulis DG et al.: Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a metaanalysis. J Clin Pharm Ther 2010; 35: 639–656.
• Wojtera M, Sobów T: Stosowanie pregabaliny w leczeniu uogólnionych zaburzeń lękowych. Czy należy bać się wysokich dawek? Psychiatr Psychol Klin 2016; 16: 91–98.
• Zaccara G, Gangemi P, Perucca P et al.: The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011; 52: 826–836.
• Zaccara F, Giovannelli F, Giorgi FS et al.: Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol 2017; 73: 811–817.
• Zaccara G, Perucca P, Gangemi PF: The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol 2012; 68: 903–912.

• Document Type: article